Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Down 21.6% in August

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totalling 90,900 shares, a decline of 21.6% from the August 15th total of 115,900 shares. Approximately 3.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 496,100 shares, the days-to-cover ratio is presently 0.2 days.

Tenax Therapeutics Price Performance

Shares of Tenax Therapeutics stock traded up $0.12 during trading hours on Friday, hitting $3.81. The company’s stock had a trading volume of 65,933 shares, compared to its average volume of 314,326. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $61.20. The business has a fifty day moving average of $3.68 and a 200 day moving average of $3.66.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share for the quarter, topping the consensus estimate of ($1.99) by $0.16. As a group, analysts predict that Tenax Therapeutics will post -6.68 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Tenax Therapeutics in a research report on Tuesday, September 10th. They set a “sell” rating for the company.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.